Cite
HARVARD Citation
Grosicki, S. et al. (2020). Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 396 (10262), pp. 1563-1573. [Online].